Wall Street analyst estimates for PepGen Inc. (PEPG): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Valuation Ratios
| Price / Book | 1.70 |
| EV / EBITDA | -3.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $106000 | 0 | 0 | 0 | $1.2M | $1.5M | $1.4M |
| Gross Profit | -$106000 | 0 | 0 | 0 | -$1.2M | -$1.5M | -$1.4M |
| Research & Development | $620000 | $1.1M | $23.8M | $54.1M | $68.1M | $76.5M | $71.0M |
| Selling, General & Admin | $628000 | $853000 | $8.1M | $14.2M | $16.6M | $21.3M | $22.6M |
| Operating Expenses | $1.2M | $1.9M | $27.1M | $68.3M | $83.6M | $96.2M | $92.2M |
| Operating Income | -$1.4M | -$1.9M | -$27.1M | -$68.3M | -$84.8M | -$97.7M | -$93.6M |
| EBITDA | -$1.2M | -$1.8M | -$27.1M | -$64.9M | -$77.4M | -$89.1M | -$88.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$1.3M | -$1.9M | -$27.3M | -$65.4M | -$78.6M | -$90.6M | -$89.6M |
| Income Tax | 0 | 0 | 0 | $3.7M | $73000 | -$617000 | $49000 |
| Net Income | -$1.3M | -$1.9M | -$27.3M | -$69.1M | -$78.6M | -$90.0M | -$89.7M |
| EPS | $-0.06 | $-0.53 | $-1.22 | $-4.42 | $-3.30 | $-2.85 | $-2.12 |
| EPS (Diluted) | $-0.06 | $-0.18 | $-1.22 | $-4.42 | $-3.30 | $-2.85 | $-2.12 |
| Shares Outstanding (Diluted) | $22.4M | $22.4M | $22.4M | $15.6M | $23.8M | $31.6M | $42.2M |
Price
| Price | $2.90 |
| Market Cap | $201M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALEC · APLT · CRBP · CRDF · CYBN · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of PEPG: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks